HIMS Stock Recent News

Hims & Hers Health, Inc. Q1 results beat the Street's expectations, as I anticipated in February. The company reaffirmed FY 2025 guidance and increased the EBITDA range for the year. That said, I believe the rally on May 6 was driven by the high short interest and not by fundamentals. The availability of Eli Lilly and Novo Nordisk weight loss drugs on the Hims platform is significant, but the easing of drug shortages could affect Q2 subscriber numbers.

Hims & Hers Health (HIMS) released first-quarter earnings after the closing bell on Monday and saw shares surge on the robust numbers.

Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel effect driven by machine learning and big data analytics. Risks include the untested business model, potential legal issues, and the complexity of international expansion, but the growth potential presented far outweighs these concerns.

Hims & Hers (HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a short squeeze likely helped, which Travis Hoium discusses in this video.

Investors are buying Hims & Hers Health (HIMS 19.77%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of Eli Lilly (LLY -6.21%) and Novo Nordisk (NVO -4.31%), the latter of which is a Hims & Hers partner now.

Hims & Hers Health Inc   (NYSE:HIMS) beat top- and bottom-line estimates for the first quarter, with net profits seeing a 300% jump.

Hims & Hers Health, Inc. impressed with strong Q1 earnings, subscriber growth, and a promising partnership with Novo Nordisk, but didn't guide as well as we all hoped. The two reasons I'm buying are 1. The partnership with Novo should expand to include Ozempic and 2. Oral pill approval from the FDA should be achieved and boost financials. I think we're still at the start of Hims' comeback story, and the stock is still cheap considering its upside potential.

Shares of Hims & Hers Health (HIMS) surged 10% on Tuesday morning after the telehealth company posted first-quarter results that far surpassed Wall Street expectations and unveiled an ambitious roadmap targeting $6.5 billion in revenue by 2030. Revenue in the quarter more than doubled to $586 million, up 111% from a year earlier and well ahead of analysts' average estimate of $538.9 million.

Live Updates Live Coverage Has Ended HIMS forward guidance is exciting 5:02 pm by Joel South HOLY MOLY $HIMS JUST GUIDED TO $6.5B IN 2030 SALES WITH 20% EBITDA MARGINS pic.twitter.com/9w2fDU8rlQ — Shay Boloor (@StockSavvyShay) May 5, 2025 Insane growth numbers 4:21 pm by Joel South $HIMS These YoY growth numbers are on level with $NVDA in 2023. FCF is +321% Net Income is +345% This is a monster pic.twitter.com/wMWgEewFkJ — The Long Investor (@TheLongInvest) May 5, 2025 Earnings are out 4:15 pm by Joel South Hims & Hers reported strong financial results for the first quarter of 2025, with revenue rising 111% year-over-year to $586.0 million. Net income for the quarter was $49.5 million, up from $11.1 million in Q1 2024. The company posted adjusted EBITDA of $91.1 million, compared to $32.3 million a year ago, bringing adjusted EBITDA margin to 16%. The company’s subscriber base grew to 2.4 million, reflecting 38% growth from the prior year. Monthly online revenue per average s

There are only a few companies that come around every half-decade or so that really get the gears turning in terms of having the right fundamental makeup for value investors. It just so happens that these companies (when caught early on) are too small to even be on the radar of the bigger sharks in the financial markets, which is where average retail investors get the chance to act on an inherent advantage.